Balanced news tone
News Sentiment
IFRX sentiment intelligence
InflaRx N.V. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
52 relevant articles
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-8.5% over one week, +28.1% over four weeks, trend active, and near fair-value range.
IFRX - InflaRx NV Revenue Breakdown
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
80/100 classification
One-week reaction
-8.5%
Price reacting lower
Trend fit
Trend active
28.1% over four weeks
Fair value
23.4%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
13
Neutral
34
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
MarketBeat
Direct company coverage
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 15:53
- Source
- MarketBeat
GlobeNewswire
Direct company coverage
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- GlobeNewswire
European Biotechnology Magazine
Direct company coverage
InflaRx attracts strong investor interest with US share offering turning to kidney
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- European Biotechnology Magazine
Stock Titan
Direct company coverage
InflaRx (NASDAQ: IFRX) raises $150M in underwritten share sale
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- Stock Titan
Market source
Direct company coverage
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- Market source
GlobeNewswire
Direct company coverage
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 12:30
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 12:25
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Funded through 2029, InflaRx expands izicopan into kidney diseases
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
InflaRx prices $150M stock sale to fund pipeline and working capital
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 11:30
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
No conference call: InflaRx to post Q1 2026 results on May 7
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 May 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
InflaRx (Nasdaq: IFRX) back in line with Nasdaq minimum bid price rule
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Nasdaq closes InflaRx listing issue after stock holds above $1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 02 Feb 2026 08:00
- Source
- Market source
Stock Titan
Direct company coverage
Inflarx (IFRX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2025 23:56
- Source
- Stock Titan
MarketBeat
Direct company coverage
InflaRx (IFRX) Stock Price, News & Analysis $IFRX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Nov 2017 04:53
- Source
- MarketBeat
TradingView
Direct company coverage
IFRX Stock Price and Chart — NASDAQ:IFRX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Nov 2017 03:02
- Source
- TradingView